Evidence map›Paper›PMID 41870550›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

A deep learning PET/CT biomarker for early progression (POD24) and survival stratification in follicular lymphoma: a multicenter study.

Hexiao Huang, Tingrui Zhang, Zekun Jiang, Zitong Zhang, Qiuhui Jiang, Yue Teng, Hang Zhou, Chongyang Ding, Jingyan Xu, Ming Jiang and 4 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Hexiao Huang *Department of Nuclear Medicine, West China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu, Sichuan, 610041, People's Republic of China.
Tingrui Zhang *Sichuan University - Pittsburgh Institute, Sichuan University, Chengdu, 610000, China.
Zekun Jiang *West China Biomedical Big Data Center, West China Hospital, Sichuan University, No.37, Guoxue Alley, Chengdu, Sichuan, China.
Zitong ZhangDepartment of Nuclear Medicine, West China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu, Sichuan, 610041, People's Republic of China.
Qiuhui JiangDepartment of Hematology, Institute of Hematology, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, No.55 Zhenhai Road, Xiamen, China.
Yue TengDepartment of Nuclear Medicine, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
Hang ZhouDepartment of Nuclear Medicine, Qilu Hospital of Shandong University, Shandong, China.
Chongyang DingDepartment of Nuclear Medicine, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Jingyan XuDepartment of Nuclear Medicine, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
Ming JiangDepartment of Oncology, West China Hospital of Sichuan University, Chengdu, China.
Bing XuDepartment of Hematology, Institute of Hematology, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, No.55 Zhenhai Road, Xiamen, China. xubingzhangjian@126.com.
Chong JiangDepartment of Nuclear Medicine, West China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu, Sichuan, 610041, People's Republic of China. jiangc_nju@163.com.
Rong TianDepartment of Nuclear Medicine, West China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu, Sichuan, 610041, People's Republic of China. rongtiannuclear@126.com.ORCID 0000-0002-5191-9004
Kang LiWest China Biomedical Big Data Center, West China Hospital, Sichuan University, No.37, Guoxue Alley, Chengdu, Sichuan, China. likang@wchscu.cn.

Funding

Chengdu Municipal Science and Technology Program 2024-YF05-00632-SNChina Postdoctoral Science Foundation 2024M762244Innovative Research Group Project of the National Natural Science Foundation of China 2025HXBH087National Natural Science Foundation of China 81971653National Natural Science Foundation of China 82572319
6 · The paper itself

Abstract

objectiveTo develop and validate a prognostic imaging biomarker derived from baseline [¹⁸F]FDG PET/CT using tabular deep learning for prediction of progression of disease within 24 months (POD24) and survival risk stratification in patients with follicular lymphoma (FL).

methodsThis retrospective multicenter study included 309 patients with newly diagnosed FL (grades 1-3a) from five independent medical centers. Tumor volumes segmented from baseline [¹⁸F]FDG PET and CT images were used to extract high-throughput radiomic features. Five conventional machine learning algorithms and four advanced tabular deep learning models were developed and compared. The predictive output of the GAMformer model was defined as the deep learning score (DLS). The DLS was integrated with clinical variables and PET metabolic parameters to construct a multiparametric model in the training cohort. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), calibration curves, and decision curve analysis, and further validated in validation cohort.

resultsDuring a median follow-up of 44 months, POD24 occurred in 55 patients. The DLS demonstrated strong predictive performance for POD24 (training AUC = 0.857; validation AUC = 0.753). The multiparametric model further improved discrimination, achieving AUCs of 0.882 in the training cohort and 0.797 in the validation cohort, outperforming FLIPI, FLIPI-2, and PRIMA-PI. Calibration showed good agreement, and decision curve analysis indicated higher net clinical benefit. The DLS stratified survival risk (P < 0.05) and remained predictive of survival and POD24 across histologic grades.

conclusionsThe DLS derived from baseline [¹⁸F]FDG PET/CT enables POD24 prediction and accurate survival risk stratification in FL, supporting its potential role in precision management.

Indexed as

Deep LearningLymphoma, FollicularPositron Emission Tomography Computed TomographyAgedDisease ProgressionFemaleFluorodeoxyglucose F18HumansMaleMiddle AgedPredictive Learning ModelsPrognosisRadiomicsRetrospective StudiesSurvival AnalysisFluorodeoxyglucose F18Deep learningFollicular lymphomaPET/CTPOD24RadiomicsTabular foundation model

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.